Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The first-generation HMA azacitidine and decitabine have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Stomper, Julia, Rotondo, John Charles, Greve, Gabriele, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257497/
https://www.ncbi.nlm.nih.gov/pubmed/33958699
http://dx.doi.org/10.1038/s41375-021-01218-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257497/
https://www.ncbi.nlm.nih.gov/pubmed/33958699
http://dx.doi.org/10.1038/s41375-021-01218-0

Ejemplares similares